thiopalmitic acid S-methyl ester | 244050-82-6

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 脂肪酰基
• 英文名称: thiopalmitic acid S-methyl ester
• 英文别名: Thiopalmitinsaeure-S-methylester；S-methyl hexadecanethioate
• CAS: 244050-82-6
• 化学式: C₁₇H₃₄OS
• 分子量: 286.522
• InChiKey: GVSCLAAEYLXQJT-UHFFFAOYSA-N

物化性质

• 沸点：
  366.9±11.0 °C(Predicted)
• 密度：
  0.894±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  7.2
• 重原子数：
  19
• 可旋转键数：
  15
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.94
• 拓扑面积：
  42.4
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  thiopalmitic acid S-methyl ester 在 1,4-二氧六环 、 镍 作用下， 生成 1-十六烷醇
  参考文献：
  名称：

  一种将羧酸转化为伯醇的方法

  摘要：

  DOI：

  10.1002/hlca.19460290318
• 作为产物：
  描述：

  甲硫醇 、 棕榈酰氯 在 吡啶 、 苯 作用下， 生成 thiopalmitic acid S-methyl ester
  参考文献：
  名称：

  一种将羧酸转化为伯醇的方法

  摘要：

  DOI：

  10.1002/hlca.19460290318

文献信息

• Ralston; Segebrecht; Bauer, Journal of Organic Chemistry, 1939, vol. 4, p. 503,504
  作者：Ralston、Segebrecht、Bauer

  DOI：——

  日期：——
• WEIGHT LOSS COMPOSITIONS AND USES THEREOF
  申请人：Owoc John H.

  公开号：US20100081626A1

  公开（公告）日：2010-04-01

  This invention provides unique and advantageous formulations and methods for weight loss.
• LIPID COMPOUNDS AND COMPOSITIONS AND THEIR OPTHALMIC USE
  申请人：BIOZEP AS

  公开号：US20190284129A1

  公开（公告）日：2019-09-19

  The invention relates to lipid compounds of formula f(1) and their pharmaceutically acceptable salts for the prevention and/or treatment of ophthalmic disorders such as retinal degenerative disorders and ocular inflammatory diseases: (I) (wherein R 1 is either a C 9 to C 22 alkyl group, or a C 9 to C 22 alkenyl group having from 1 to 6 double bonds; R 2 is selected from the group consisting of a halogen atom, a hydroxy group, an alkyl group, an alkoxy group, an alkylthio group, a carboxy group, an acyl group, an amino group, and an alkylamino group; R 3 is a hydrogen atom, or a group R 2 ; R 4 is a carboxylic acid or a derivative thereof; and X is methylene (—CH 2 —), or an oxygen or sulfur atom).
• ENGINEERED EXTRACELLULAR VESICLES AND USES THEREOF
  申请人：Codiak BioSciences, Inc.

  公开号：US20220017907A1

  公开（公告）日：2022-01-20

  The present disclosure relates to therapeutic exosomes enriched in proteins that are present in the luminal surface of exosomes. The present disclosure provides methods of manufacturing exosomes enriched in proteins that are present in the luminal surface of exosomes, method of associating a therapeutic peptide or protein to the luminal surface of exosomes, and method of use, e.g., methods of therapeutic or diagnostic use. The methods of manufacture involve generating of luminal-surface-engineered exosomes that include one or more of the EV, e.g., exosome proteins at concentrations higher that those observed in wild type exosomes, a modification or a fragment of the EV, e.g., exosome protein, or a fusion protein of the EV, e.g., exosome protein, and a payload, e.g., biologically active molecule such as a therapeutic protein.
• EXTRACELLULAR VESICLES FOR VACCINE DELIVERY
  申请人：Codiak BioSciences, Inc.

  公开号：US20220168415A1

  公开（公告）日：2022-06-02

  The present disclosure relates to extracellular vesicles (EVs), e.g., exosomes, comprising a payload (e.g., an antigen, adjuvant, and/or immune modulator) and/or a targeting moiety. Also provided herein are methods for producing the EVs (e.g., exosomes) and methods for using the EVs (e.g., exosomes) to treat and/or prevent diseases or disorders, e.g., cancer, graft-versus-host disease (GvHD), autoimmune disease, infectious diseases, or fibrotic diseases.